Investors should monitor the upcoming spin-off execution and Phase 1b data readouts for ANB033 in 2026–2027. The strong Jemperli commercial trajectory supports near-term royalty growth, while the separation creates optionality between a pure-play royalty vehicle and a clinical-stage biotech.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 4 $40.37entry
- T+1 · 9mo ago −5.40%α −4.83% · $38.19
- T+5 · 8mo ago +6.80%α +8.14% · $43.11
- T+20 · 8mo ago −6.31%α −1.89% · $37.82
- T+60 · 6mo ago +41.26%α +31.17% · $57.02
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AnaptysBio reported strong Q4 and full-year 2025 financial results driven by a surge in Jemperli royalties and milestones from GSK, including a $75M milestone payment. Collaboration revenue more than doubled, and the company confirmed progress toward a Q2 2026 spin-off of its biopharma assets into First Tracks Biotherapeutics. Despite a net loss for the year, cash remains robust at $311.6M, and the royalty outlook is bullish with >$390M in annualized royalties expected by 2029.
Key Financial Metrics
Key Facts
- Collaboration revenue was $108.2M (Q4) and $234.6M (full year 2025), up from $43.1M and $91.3M in 2024.
- Jemperli achieved $1B in global sales in Nov 2025, triggering a $75M milestone payment to Anaptys.
- Jemperli royalties grew 103% YoY to $96.0M for the year, with a $1.4B annualized run rate in Q4.
- Anaptys expects >$390M in annualized Jemperli royalties by 2029 at GSK's peak sales guidance of >$2.7B.
- Cash and investments totaled $311.6M as of Dec 31, 2025, down from $420.8M due to operating use and share repurchases.
- Company repurchased 11.2% of shares outstanding ($68.6M) under its $175M buyback program.
- Spin-off of biopharma operations into First Tracks Biotherapeutics (TRAX) on track for Q2 2026, potentially as early as late April.
- Phase 1b trials for ANB033 in celiac disease and eosinophilic esophagitis ongoing, with data expected in Q4 2026 and 2027, respectively.
Financial Impact
Revenue more than doubled YoY to $234.6M; Jemperli royalties now on a $1.4B annualized run rate, implying significant future royalty growth. Expected peak annual royalties >$390M.
Risk Factors
- Spin-off timing or structure could change, creating uncertainty.
- Clinical development risks for ANB033, rosnilimab, and ANB101 remain high.
- Future royalty payments depend on GSK achieving peak sales guidance, which is not guaranteed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3248938 |
Track record
28 reports on ANAB
10 of 18 bullish or bearish reports moved the stock their way by T+1. Best: +24.79% at T+60 after the Jun 29, 2026 report. 12 of 18 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $46.25 Now $45.73 −1.12% settles Nov 17
- Nov 12, 20264d ago Press Release Bearish 4/10 Entry $46.25 to $45.73 Now $45.73 +1.12% ▲ +1.12% −0.79% vs SPY
- Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $46.45 to $47.97 Now $45.73 −1.55% ▲ +3.27% +0.91% vs SPY
- Sep 21, 20268w ago Press Release Neutral 5/10 Entry $53.92 to $50.77 Now $45.73 −15.19% ▼ −5.84% −5.12% vs SPY
- Aug 12, 202613w ago Institutional Cluster Bullish 5/10 Entry $56.02 to $58.47 Now $45.73 −18.37% ▲ +4.37% +4.57% vs SPY
- Jun 29, 202620w ago 144 Bearish 6/10 Entry $67.50 to $65.43 Now $45.73 +32.25% ▲ +3.07% +2.93% vs SPY
- Jun 29, 202620w ago DEFA14A Neutral 2/10 Entry $67.50 to $65.43 Now $45.73 −32.25% ▼ −3.07% −2.93% vs SPY
- Jun 26, 202620w ago 144 Bearish 6/10 Entry $65.97 to $67.50 Now $45.73 +30.68% ▼ −2.32% −1.54% vs SPY
- Jun 22, 202621w ago 8-K Neutral 2/10 Entry $59.43 to $58.48 Now $45.73 −23.05% ▼ −1.60% −1.55% vs SPY
- Jun 17, 202621w ago 144 Bearish 5/10 Entry $57.51 to $59.99 Now $45.73 +20.48% ▼ −4.31% −4.63% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers